| Name | Title | Contact Details |
|---|
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.
Brauer and Associates is a Elmhurst, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WellGen is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in N Brunswick, NJ. To find more information about WellGen, please visit www.amphioncap.com
Dedicated Clinical Research II-IV is a Litchfield Park, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DCPCA is a nonprofit health reform organization founded in 1996 by health care professionals who were concerned that the shortage of primary health care in the District was contributing to increasingly poor health outcomes for DC's most vulnerable residents. With a budget of $140,000 in seed money from the federal government's Bureau of Primary Care, Sharon Baskerville became DCPCA's first executive director in 1998. As DCPCA established itself in the late 1990s, District voters elected a new mayor and six new members of the DC Council. The improved political environment made it possible for the District's budget to emerge from direct federal control. Under these new conditions, DCPCA emerged as a health reform leader and quickly became the local voice promoting progressive health care financing and public policy, galvanizing political support at the local and federal levels.